NO20220946A1 - Granuler eller granulert blanding, samt farmasøytiske preparater omfattende slike - Google Patents

Granuler eller granulert blanding, samt farmasøytiske preparater omfattende slike Download PDF

Info

Publication number
NO20220946A1
NO20220946A1 NO20220946A NO20220946A NO20220946A1 NO 20220946 A1 NO20220946 A1 NO 20220946A1 NO 20220946 A NO20220946 A NO 20220946A NO 20220946 A NO20220946 A NO 20220946A NO 20220946 A1 NO20220946 A1 NO 20220946A1
Authority
NO
Norway
Prior art keywords
granules
well
pharmaceutical preparations
granulated mixture
granulated
Prior art date
Application number
NO20220946A
Other languages
English (en)
Other versions
NO347404B1 (no
Inventor
Nathalie Bruneau
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37684496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20220946(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20220946A1 publication Critical patent/NO20220946A1/no
Publication of NO347404B1 publication Critical patent/NO347404B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20220946A 2006-09-27 2007-09-25 Granuler eller granulert blanding, samt farmasøytiske preparater omfattende slike NO347404B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06121371A EP1923053A1 (en) 2006-09-27 2006-09-27 Pharmaceutical compositions comprising nilotinib or its salt
PCT/EP2007/060165 WO2008037716A2 (en) 2006-09-27 2007-09-25 Pharmaceutical compositions comprising nilotinib or its salt

Publications (2)

Publication Number Publication Date
NO20220946A1 true NO20220946A1 (no) 2009-04-24
NO347404B1 NO347404B1 (no) 2023-10-16

Family

ID=37684496

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20220946A NO347404B1 (no) 2006-09-27 2007-09-25 Granuler eller granulert blanding, samt farmasøytiske preparater omfattende slike
NO20091501A NO346639B1 (no) 2006-09-27 2007-09-25 Farmasøytiske preparater og fremgangsmåte for fremstilling derav

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20091501A NO346639B1 (no) 2006-09-27 2007-09-25 Farmasøytiske preparater og fremgangsmåte for fremstilling derav

Country Status (34)

Country Link
US (2) US8293756B2 (no)
EP (4) EP1923053A1 (no)
JP (2) JP5567340B2 (no)
KR (2) KR20090076931A (no)
CN (2) CN104306350A (no)
AR (1) AR062980A1 (no)
AU (1) AU2007301977B2 (no)
BR (1) BRPI0719438B1 (no)
CA (1) CA2662571C (no)
CL (1) CL2007002766A1 (no)
CO (1) CO6160288A2 (no)
CY (2) CY1117021T1 (no)
DK (2) DK3984528T3 (no)
ES (3) ES2957912T3 (no)
FI (2) FI2068839T4 (no)
HR (2) HRP20151383T4 (no)
HU (2) HUE063083T2 (no)
IL (1) IL197496A (no)
JO (1) JO3757B1 (no)
LT (1) LT3984528T (no)
MA (1) MA30807B1 (no)
MX (1) MX2009003184A (no)
MY (1) MY148237A (no)
NO (2) NO347404B1 (no)
NZ (1) NZ575317A (no)
PE (2) PE20081379A1 (no)
PL (2) PL2068839T5 (no)
PT (2) PT2068839E (no)
RU (1) RU2469707C2 (no)
SI (2) SI3984528T1 (no)
TN (1) TN2009000093A1 (no)
TW (3) TW201418245A (no)
WO (1) WO2008037716A2 (no)
ZA (1) ZA200901511B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US8933037B2 (en) 2009-09-28 2015-01-13 Medizinische Universitat Wien Methods involving PDGFRBETA inhibitors
JP5948246B2 (ja) 2009-10-23 2016-07-06 ノバルティス アーゲー Ｂｃｒ−ａｂｌ、ｃ−ｋｉｔ、ｄｄｒ１、ｄｄｒ２またはｐｄｇｆ−ｒのキナーゼ活性によって仲介される増殖性障害およびその他の病態の治療方法
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2011CH01887A (no) * 2011-06-02 2012-12-14
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN102321073A (zh) * 2011-08-12 2012-01-18 西安交通大学 一种尼罗替尼的制备方法
RU2014120792A (ru) 2011-10-28 2015-12-10 Новартис Аг Способ лечения стромальных опухолей желудочно-кишечного тракта
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
US9301957B2 (en) 2011-11-14 2016-04-05 Novartis Ag Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
SG11201401476TA (en) * 2011-11-14 2014-10-30 Novartis Ag Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
IN2014DN10801A (no) 2012-07-11 2015-09-04 Novartis Ag
EP2988729A1 (en) 2013-04-25 2016-03-02 Sun Pharmaceutical Industries Limited Pharmaceutical gastro-retentive solid oral dosage form of nilotinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
EP3189045B1 (en) * 2014-08-11 2022-02-09 Sun Pharmaceutical Industries Limited Novel salts of nilotinib and polymorphs thereof
US10045987B2 (en) * 2014-08-28 2018-08-14 Codexis, Inc. Imidazoyl anilide derivatives and methods of use
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
EP3429589B1 (en) * 2016-03-17 2022-12-14 Sun Pharmaceutical Industries Ltd Pharmaceutical composition of nilotinib
CN107582531B (zh) * 2016-07-06 2020-12-29 四川科伦药物研究院有限公司 一种利伐沙班固体制剂及其制备方法
CN107320460B (zh) * 2017-08-04 2020-11-03 北京化工大学 一种尼罗替尼口服纳米制剂及其制备方法
CN107441094B (zh) * 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
EP4096791A1 (en) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
JP7489849B2 (ja) * 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤
MX2023003556A (es) 2020-09-29 2023-06-13 Shenzhen Pharmacin Co Ltd Composiciones farmaceuticas.
CN115154437A (zh) * 2021-04-01 2022-10-11 齐鲁制药有限公司 一种含有盐酸尼洛替尼的药物组合物及其制备方法
MX2023015480A (es) 2021-06-19 2024-01-19 Helm Ag Composicion granulada que comprende nilotinib.
WO2023285981A1 (en) * 2021-07-15 2023-01-19 Torrent Pharmaceuticals Limited Stable pharmaceutical liquid composition of nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
EP4642435A1 (en) 2022-12-29 2025-11-05 Renata Pharmaceuticals (Ireland) Limited Pharmaceutical suspension of nilotinib
WO2024194718A1 (en) * 2023-03-22 2024-09-26 Unichem Laboratories Limited A stable pharmaceutical composition and process for preparing thereof
CN116854638A (zh) * 2023-06-05 2023-10-10 南华大学 一种含烷基链的氨基酸甲酯类化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005281A1 (en) * 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases
WO2006089781A1 (en) * 2005-02-25 2006-08-31 Novartis Ag Pharmaceutical combination of bcr-abl and raf inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP3125221B2 (ja) * 1990-09-01 2001-01-15 大正製薬株式会社 ソファルコン含有固形製剤
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
DE122007000079I2 (de) 1996-07-24 2010-08-12 Celgene Corp Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
FR2783421B1 (fr) * 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
PT1200090E (pt) 1999-08-03 2013-11-25 Icos Corp Formulação farmacêutica à base de um beta-carbolina e seu uso para tratar a disfunção sexual.
PL351069A1 (en) * 1999-12-08 2003-03-10 Pharmacia Corp Valdecoxib compositions
EP1248869A2 (en) 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
CN1674877A (zh) * 2002-06-07 2005-09-28 兰贝克赛实验室有限公司 控释的多单位药物释放系统
ES2379075T3 (es) * 2002-11-26 2012-04-20 Universiteit Gent Proceso y aparato para granulación húmeda continua de material en polvo
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
BRPI0413277A (pt) * 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
TR200301553A1 (tr) 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
WO2005065653A1 (en) * 2003-12-19 2005-07-21 E.I. Du Pont De Nemours And Company Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
EP1776102A1 (en) 2004-07-28 2007-04-25 Ranbaxy Laboratories Limited Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation
WO2006038552A1 (ja) * 2004-10-01 2006-04-13 Eisai R & D Management Co., Ltd. 微粒子含有組成物およびその製造方法
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
ATE525073T1 (de) * 2005-01-28 2011-10-15 Novartis Ag Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
JP5546860B2 (ja) * 2006-08-16 2014-07-09 ノバルティス アーゲー 高結晶性治療化合物の固体分散体を製造するための方法
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005281A1 (en) * 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases
WO2006089781A1 (en) * 2005-02-25 2006-08-31 Novartis Ag Pharmaceutical combination of bcr-abl and raf inhibitors

Also Published As

Publication number Publication date
TWI540128B (zh) 2016-07-01
BRPI0719438B1 (pt) 2022-04-19
CN104306350A (zh) 2015-01-28
HUE063083T2 (hu) 2023-12-28
SI2068839T2 (sl) 2023-01-31
AU2007301977A1 (en) 2008-04-03
TW201418245A (zh) 2014-05-16
CY1126116T1 (el) 2023-11-15
HRP20151383T1 (hr) 2016-01-15
PL2068839T3 (pl) 2016-06-30
ES2957912T3 (es) 2024-01-29
LT3984528T (lt) 2023-08-10
WO2008037716A3 (en) 2008-07-17
CA2662571A1 (en) 2008-04-03
EP3984528A1 (en) 2022-04-20
EP2068839A2 (en) 2009-06-17
CL2007002766A1 (es) 2008-08-08
SI2068839T1 (sl) 2016-02-29
US20130023549A1 (en) 2013-01-24
TWI428333B (zh) 2014-03-01
HUE028204T2 (en) 2016-12-28
KR20090076931A (ko) 2009-07-13
RU2469707C2 (ru) 2012-12-20
EP3984528B1 (en) 2023-07-05
HRP20151383T4 (hr) 2023-03-03
HK1133193A1 (en) 2010-03-19
CY1117021T1 (el) 2017-04-05
BRPI0719438A2 (pt) 2013-12-10
NO347404B1 (no) 2023-10-16
RU2009115782A (ru) 2010-11-10
US20100087463A1 (en) 2010-04-08
DK2068839T3 (da) 2016-01-11
DK3984528T3 (da) 2023-07-31
IL197496A0 (en) 2009-12-24
AU2007301977B2 (en) 2011-09-08
MX2009003184A (es) 2009-04-03
CO6160288A2 (es) 2010-05-20
TW200821298A (en) 2008-05-16
CA2662571C (en) 2016-09-27
FI2068839T4 (fi) 2023-01-31
US8293756B2 (en) 2012-10-23
JP2010504942A (ja) 2010-02-18
ZA200901511B (en) 2010-02-24
TW201418244A (zh) 2014-05-16
WO2008037716A2 (en) 2008-04-03
EP1923053A1 (en) 2008-05-21
IL197496A (en) 2016-04-21
JP5567340B2 (ja) 2014-08-06
JO3757B1 (ar) 2021-01-31
ES2556625T3 (es) 2016-01-19
EP2068839B2 (en) 2022-10-12
FI3984528T3 (fi) 2023-07-27
EP3009128A1 (en) 2016-04-20
PT3984528T (pt) 2023-08-07
PT2068839E (pt) 2015-12-30
KR101598747B1 (ko) 2016-03-02
JP2014065715A (ja) 2014-04-17
NZ575317A (en) 2011-12-22
ES2951547T3 (es) 2023-10-23
PL2068839T5 (pl) 2023-01-30
MY148237A (en) 2013-03-29
HRP20230753T3 (hr) 2023-10-27
CN101516344A (zh) 2009-08-26
TN2009000093A1 (en) 2010-08-19
NO346639B1 (no) 2022-11-07
KR20140121903A (ko) 2014-10-16
AR062980A1 (es) 2008-12-17
PE20081379A1 (es) 2008-11-27
PE20120626A1 (es) 2012-06-07
EP3009128B1 (en) 2023-07-05
MA30807B1 (fr) 2009-10-01
SI3984528T1 (sl) 2023-09-29
NO20091501L (no) 2009-04-24
PL3984528T3 (pl) 2023-08-28
ES2556625T5 (es) 2023-03-02
US8501760B2 (en) 2013-08-06
EP2068839B1 (en) 2015-09-23

Similar Documents

Publication Publication Date Title
NO20220946A1 (no) Granuler eller granulert blanding, samt farmasøytiske preparater omfattende slike
PT2939688T (pt) Composições farmacêuticas compreendendo neurotoxina botulínica
IL205036A (en) Polypeptides, pharmaceutical preparations containing their uses and a nucleic acid encoding them
WO2008015220A8 (en) Granule and orally disintegrating tablet comprising oxycodone
EP2233504A4 (en) A ERYTHROPOIETIN MIMETIC PEPTIDE DERIVATIVE AND ITS PHARMACEUTICAL SALT, ITS PREPARATION AND ITS APPLICATIONS
FI20070521A0 (fi) Rakeita, tabletteja ja rakeistusmenetelmä
NL2000690A1 (nl) Gestabiliseerde farmaceutische samenstellingen omvattende fesoterodine.
IL202443B (en) Nucleic acid encoding it and a pharmaceutical preparation containing the protein, a fusion protein for nucleic acid
HUS1400051I1 (hu) Lurazidont tartalmazó gyógyászati készítmény
EP1872294A4 (en) VIRTUAL EARTH
DK2118006T3 (da) Fremgangsmåde til fremstilling af silicapræparater, silicapræparater samt anvendelser deraf
BRPI0907650A2 (pt) Composições farmacêuticas compreendendo degradadores de produtos finais de glicosilação avançada (ages) e drogas adjuvantes como drogas anti-hipertensivas, antidiabéticas e etc
IL195813A0 (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
DK1877409T3 (da) Substituerede pyrrolopyridiner, sammensætninger, der indeholder samme, fremgangsmåde til fremstilling deraf samt anvendelse deraf
EP1871347A4 (en) PHARMACEUTICAL COMPOSITION
DK1910288T3 (da) 3-aminocarbazolsammensætninger, farmaceutiske sammensætninger, der indeholder disse, samt fremgangsmåde til deres fremstilling
BRPI0822066A2 (pt) derivados diolatos daizênio, o respectivo processo de preparo e as composições farmacêuticas que os contêm
BRPI0717025A2 (pt) Composição adoçantes sem-escoamento livre e coesas contendo um agente aglomerante
EP1937255A4 (en) PHARMACEUTICAL COMPOSITION
WO2007100241A8 (en) Information-processing system for the purpose of market research
DK2001445T3 (da) Farmaceutiske sfæroider
BRPI0814407A2 (pt) derivados naftalênicos, processo de preparação e composições farmacêuticas contendo os mesmos
BRPI0717453A2 (pt) Derivados indólicos, o respectivo processo de preparo e as composições farmacêuticas que os contêm
ZA200808768B (en) Pharmaceutical composition containing the NMB0606 protein